Introduction
Around 1.5 million Sri Lankan adults suffer from diabetes and the number is expected to rise up to 2.1 million by the year 2030. Diabetes mellitus is the leading cause of myocardial infarction, stroke, chronic kidney disease, blindness in adults and amputations. Prevention of these complications requires evidence based multiple risk factor approach and patient centred self management approach with multidisciplinary support. Early intensive glycaemic control decreases microvascular complications and improves cardiovascular outcomes.
HbA1C
≤7.0%
Pre-prandial capillary 70-130 mg/dL plasma glucose (3.9-7.2 mmol/L) Peak post-prandial <180 mg/dL capillary plasma glucose (<10.0 mmol/L)
• More stringent HbA1C targets, i.e.: 6.0-6.5% might be considered in selected patients (with short disease duration, long life expectancy, no significant CVD and also before conception in women) if this can be achieved without significant hypoglycaemia or other adverse effects of treatment.
• Less stringent HbA1C targets, i.e.: 7.5-8.0% is appropriate for patients with severe hypoglycaemia, limited life expectancy, advanced complications and extensive co-morbid conditions.
Glycaemic control -glycaemic targets

Monitoring of glycaemic control
Ideally a combination of HbA1C and self monitoring with capillary glucose will give optimal results.
Self monitoring of blood glucose (SMBG)
• Refers to monitoring by the patient using a glucometer • Recommended for patients on multiple insulin doses or insulin pump therapy • The practice of monitoring glucose control with a monthly FPG is suboptimal and has many limitations.
HbA1C
HbA1C should be measured by a NGSP certified method (standardised to the DCCT reference)
Frequency of HbA1C
• When glycaemic control is stable, A1C test is recommended 6 monthly.
• When glycaemic control is inadequate, A1C test is recommended 3 monthly.
• HbA1C can be used to check the accuracy of SMBG results and the adequacy of testing schedules.
Limitations of HbA1C
• In patients with haemoglobinopathy or high red cell turnover values may be discordant with clinical status.
• In patients who have high glycaemic variability self monitoring of blood glucose is recommended. • Total daily insulin requirement is 0.5-1U/kg/day in type 1 diabetes but can be much higher in type 2 diabetes.
Treatment of Type 2 Diabetes
• When basal insulin is started metformin is often continued.
• Continuing the secretagogues may minimize initial deterioration of glycaemic control but should be avoided once prandial insulin regimens are employed.
• TZDs should be reduced in dose or stopped to avoid oedema and excessive weight gain.
Clinical guidelines: The Endocrine Society of Sri Lanka
Acarbose 150-600 mg in Frequent dosing divided doses schedule before meals
DPP-4 inhibitors
No 
Clinical guidelines: The Endocrine Society of Sri Lanka
Type 1 diabetes mellitus (T1DM) is the most common form of diabetes among children. However, the incidence of type 2 diabetes mellitus (T2DM) is increasing among the youth, in parallel with the increasing prevalence of obesity.
Management
• Children with diabetes should be referred to a specialized centre.
• They should be managed by a diabetes team/ multidisciplinary team (paediatric endocrinologist/ paediatrician, nurse educator, dietician/nutritionist, psychologist, social worker).
• Several aspects have to be addressed in the management of a child with T1DM (e.g. growth, unpredictable dietary and exercise patterns and high risk for hypoglycaemia).
• Education of parents/care givers and teachers is crucial for optimum care of the child.
• Diet -Calculate the energy requirement based on the weight and translate the carbohydrate proportion into portions and distribute throughout the day as 3 main meals and 3 snacks. o Regimen -twice daily or basal-bolus regimen.
• Exercise -no restriction in physical activity. A change in the insulin dose or snack may be necessary during the activity.
• Sick day management -insulin should never be stopped. Dose adjustments will be necessary depending on intake of food.
• Hypoglycaemia
Plasma glucose level below 72 mg/dL (4 mmol/L). Clinical presentations are variable.
Management of hypoglycaemia
• If conscious: oral glucose/sweetened drink followed by a snack.
• If unconscious or convulsing: Intravenous dextrose or glucagon SC (30 μg/kg).
• At home/school as a first aid measure, apply glucose on the inner surface of child's lips with the finger.
Careful consideration is essential prior to deciding on the regimen.
• Oral agents may be considered in type 2 diabetes and MODY.
• Glycaemic control -targets are less stringent than for adults. Home blood glucose monitoring is essential for successful glycaemic control. • α-glucosidase inhibitors -targets postprandial hyperglycaemia and have a low hypoglycaemic risk, attractive for older patients. However, gastrointestinal intolerance may be limiting its use.
Age group
• GLP-1 RA -low risk of hypoglycaemia, but associated nausea and weight loss may cause problems in frail older patients.
• DPP-4 inhibitors -useful for postprandial hyperglycaemia, impart little risk for hypoglycaemia, well tolerated, therefore potential benefits for older patients.
• Insulin therapy -risk of hypoglycaemia should be considered before commencement. Use requires that patients or caregivers have good visual and motor skills and cognitive ability.
• Drugs should be started at the lowest dose and titrated up gradually.
• Polypharmacy may affect compliance, cause drug interactions and worsen adverse effects such as hypoglycaemia and hypotension.
Diabetes in Older Adults
IADPSG diagnostic criteria for 2 hrs 75 g OGTT -if any one value meets or exceeds: Fasting 92 mg/ dl (5.1 mmol/L), one hour 180 mg/dl (10 mmol/L) and 2 hr 153 mg/dl (8.5 mmol/L). This is not validated in South Asian setting.
Initial screening at ANC booking: Check 2 hour PPG (after a standard Sri Lankan meal) and if this exceeds 120 mg/dl proceed to 75g OGTT in first trimester to detect previously undiagnosed T2DM.
Diabetes in Pregnancy
Diagnosis of gestational diabetes
WHO criteria of 2 hour PPG more than 140 mg/dl is useful to identify pre-pregnant diabetes.
Tight glycaemic control in the first trimester is crucial to prevent foetal congenital malformations. Therefore preconception planning is of vital importance.
Pre-pregnancy counselling and workup
• Achieve the best possible glycaemic control before conception.
• Target HbA1C <6.5% • Women with an elevated HbA1C value above 8.0%
should be discouraged from becoming pregnant until their control is improved and appropriate contraceptive advice should be provided.
• Initiate insulin to get ideal control.
• Use of metformin should be under specialist care.
• Assess for established diabetes complications before conception.
o Detailed renal and retinal assessment.
• Stop ACE inhibitors, ARBs, statins, fibrates and niacin before conception or as soon as pregnancy is confirmed.
• Alternative antihypertensive agents suitable for use during pregnancy (nifedepine, methyldopa, prazocin, hydralazine, and labetalol) should be substituted.
• Women with diabetes with unplanned or unexpected pregnancy, should be referred to a specialist immediately.
Management of diabetes during pregnancy
• Encourage self-monitoring of blood glucose levelsboth fasting and postprandial, preferably 2 hrs after a meal.
• Women with insulin-treated diabetes should test blood glucose levels at bed time.
Lifestyle management
Medical nutrition therapy
• All advice should be individualized and should be • Women with pre-existing diabetes who had previous nutritional advice need to be reviewed and revised during pregnancy.
• Dietary advice should be reemphasized at each clinic visit considering the pattern of weight gain.
Exercise
• A minimum of 30 minutes exercise on most days of the week is recommended during a normal pregnancy (e.g. walking, swimming, cycling and aerobics), unless advised against by a specialist.
Insulin use during pregnancy
• If lifestyle measures fail to achieve control within one to two weeks start insulin.
• Split mixed or basal bolus regimens are the most suitable.
• Women on insulin should be advised of the risks of hypoglycaemia particularly in the first trimester.
Oral glucose-lowering agents in pregnancy
• Metformin can be used with caution in pregnancy and breastfeeding.
• All other oral hypoglycaemic agents should be discontinued before pregnancy and insulin substituted.
After delivery
• Women with pre-existing diabetes before conception: • The "gold standard" is plasma blood glucose (FBG, PPG).
• Treatment decisions can be made by using daily glucose monitoring (SMBG).
Diabetes in Chronic Kidney Disease
Pharmacological treatment
• Clearance of many drugs and insulin is decreased by kidney disease leading to frequent hypoglycaemic episodes.
• The greatest risk is for patients with moderate to severe CKD (stages 3-5).
Insulin
• All the available insulin preparations can be used in CKD.
• Insulin types and doses must be individualized for each patient and their level of CKD. • Blood glucose level should be maintained between 140 and 180 mg/dL (7.8-10 .0 mmol/L) while the lower limit is preferred.
Class
• In selected patients lower blood glucose target (<140 mg/dL) may be appropriate. However, targets less than 110 mg/dL (6.1 mmol/L) are not recommended.
• o Check blood glucose every 2 hours before and during surgery.
• "Sliding scale insulin" is NOT recommended for the post-operative management of diabetes when used as sole therapy.
HbA1C:
The predominant form of glycated haemoglobin, present in red blood cells, and formed when the normal haemoglobin A reacts non-enzymatically with glucose. As the reaction is slow and only concentration dependent, the amount of HbA1C formed is proportional only to the concentration of HbA and glucose. As HbA remains in the circulation for around 3 months, the amount of HbA1C present, expressed as a percentage of HbA, is proportional to the glucose concentration over that time.
Aerobic exercise: Constant moderate intensity work that uses up oxygen at a rate in which the cardio respiratory system can replenish oxygen in the working muscles.
Resistance training:
Resistance training works to increase muscle strength and endurance by doing repetitive exercises with weights, weight machines, or resistance bands.
α-Glucosidase inhibitors: Group of drugs which inhibit the digestion of complex carbohydrates in the gut, and thus flatten the post-meal blood glucose excursion.
Thiazolidinediones: A group of drugs which improve insulin sensitivity in people with reduced sensitivity to their own or injected insulin; presently the licensed drugs are both of the chemical group known trivially as 'glitazones' or PPAR-γ agonists.
DPP-4 inhibitors:
This class of drugs lower blood glucose levels by blocking an enzyme known as dipeptidyl peptidase IV (DPP-4), which is responsible for breaking down glucagon-like peptide-1 that stimulate the beta cells and slows gastric emptying time after a meal. If DPP-4 is inhibited, then glucagon-like peptide-1 can stimulate the release of insulin for a longer period of time, thereby lowering the glucose level in the blood and slowing the rate of absorption of food. DPP-4 inhibitors are prescribed for type 2 diabetes only.
GLP-1 RA:
GLP-1 is an incretin hormone and by definition stimulates the release of insulin from pancreatic beta cells in conjunction with carbohydrates that are absorbed from the gut. GLP-1 agonist are drugs that function as an agonist for the GLP-1 receptor. This will stimulate the beta cells to secrete more insulin in response to food in the stomach.
Insulin analogues:
A derivative of human insulin in which change of the amino-acid sequence alters duration of action after injection. This algorithm is not intended to be used for those individuals with type 1 diabetes, diabetic ketoacidosis or hyperglycaemic hyperosmolar states.
Insulin regimen:
Annexure 2
I.V. Insulin protocol for ICU patients
